Kornimate/medical-research-clean huggingface dataset:
pet/mr in the staging and efficacy evaluation of newly diagnosed nk/t-cell lymphoma

Conditions: NK/T-cell Lymphoma

Summary: this study intends to evaluate the application value of positron emission tomography/magnetic resonance (pet/mr) in the staging and efficacy evaluation of nk/t cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.

nature killer/t-cell lymphoma (nktcl) is a highly heterogeneous, aggressive lymphoma subtype with poor prognosis. ninty percent of patients have lesions involving the nasal region, other extranodal organs include adrenal glands, gastrointestinal tract, skin and so on. local tumor infiltration (bone, skin, paranasal sinus, etc) is a poor prognostic factor. therefore, nk/t-cell lymphomas have high demands on the resolution of fine anatomical structures. pet/ct and nasopharyngeal contrast-enhanced mr are routine examination methods for diagnostic staging and efficacy evaluation, but the images cannot be fused, and the divided examinations bring inconvenience to patients.

Eligibility criteria:
inclusion criteria: * pathologically diagnosed nk/t-cell lymphoma based on the who classification 2016 * age from 14 to 70 years-old * ecog 0-2 score * patients with a life expectancy of at least 6 months * patient has not been treated before for nk/t cell lymphoma * commit to abide by the research procedures and cooperate with the implementation of the whole process of research * written informed consent exclusion criteria: - subjects who meet any of the following criteria are not eligible for study entry * diagnosed aggressive nk cell leukemia * pregnant or lactating women * liver and kidney insufficiency * other pet/mr contraindications: 1. those with implanted functional electronic devices such as cardiac pacemakers 2. carotid aneurysm clipping and other implants are ferromagnetic materials 3. implanted perfusion devices such as insulin perfusion pumps 4. those who do not cooperate in examinations such as coma, mental illness, and critically ill patients 5. those who are claustrophobic * other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study
a comprehensive approach to secondary hiv prevention and care among positives

Conditions: HIV

Summary: the goal of this study is to conduct an hiv prevention intervention to train hiv seropositive drug users to be peer health educators.

the primary objective of this funded research is to conduct an hiv prevention intervention to train hiv seropositive drug users to be peer health educators to: (1) recruit their high risk social network members for voluntary hiv counseling and testing (vct) at the research clinic, (2) promote risk reduction among social network members, and (3) promote engagement in hiv care by encouraging hiv seropositive network members to schedule and keep hiv primary care appointments. there will be four types of participants in the full trial: 1) index, 2) testing network 3) longitudinal network and 4) hiv positive network participants. this longitudinal study includes baseline, 6-months, and 12-month assessments

Eligibility criteria:
inclusion criteria: index 1. 18 years old or older 2. documentation of hiv positive status 3. report one of following risk behaviors in past 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex testing network 1. 18 or older 2. provided testing coupon provided by an index participant longitudinal network participant- 1. tested hiv negative at the lighthouse via redeeming a testing coupon 2. reported interacting with index who gave the coupon at least weekly 3. report one of following risk behaviors in the prior 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex positive networks 1. hiv positive 2. report one of following risk behaviors in the prior 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex exclusion criteria: index- already enrolled in the study as a network participant testing network- already enrolled in the study as a network participant longitudinal network- a) already enrolled in the study as a network participant b) already enrolled in the study as a index participant positive network- a) already enrolled in the study as a network participant b) already enrolled in the study as a index participant

Keywords: hiv, drug use
family health after predictive huntington disease (hd) testing

Conditions: Huntington Disease

Summary: the purpose of this study is to identify health management concerns and needs of family members of asymptomatic and symptomatic persons with mutation in the gene for huntington disease (hd).

this is an observational study with three phases. in phase 1, focus groups consisting of family members of persons with hd gene mutation will be conducted and data collected to be analyzed through content analysis to identify salient themes and key issues. in phase 2, a survey instrument will be developed and field-tested in order to describe the health care needs, management strategies, and needs for health and social services of relative/significant others of asymptomatic and symptomatic persons with the mutation in the gene for hd. in phase 3, the survey will be distributed to family members of asymptomatic and symptomatic persons with mutation in the gene for hd and frequencies and comparisons of survey responses according to respondent characteristics will be reported.

Eligibility criteria:
* family members of asymptomatic and symptomatic persons with mutation in the gene for huntington disease

Keywords: patient care management family huntington's disease
antibacterial-coated sutures at time of cesarean

Conditions: Surgical Site Infection; Surgical Wound Infection; Cesarean Section; Infection; Cesarean Section Complications

Summary: abdominal closure with antibacterial-coated sutures has been shown to reduce wound infections after a number of surgical procedures, but none of the previous trials included cesarean delivery. our objective is to determine whether use of antibacterial-coated sutures reduces surgical site infection (ssi) after cesarean delivery.

a review of 18 studies demonstrated a significant benefit of antimicrobial coated sutures in reducing ssi (rcts: or 0.72; 95% ci 0.59-0.88; observational studies: or 0.58; 95% ci 0.40-0.83). as there are no clinical trials focusing on cesarean delivery, and because the risk factors and pathogenesis for post-cesarean ssi may not mirror other procedures, further data is needed before generalizing the who recommendations to cesarean procedures.

Eligibility criteria:
inclusion criteria: * 18-50 years of age. * women ≥ 24 weeks' viable gestation. * to undergo cesarean delivery. exclusion criteria: * patient unwilling or unable to provide consent. * no prenatal care or a non-resident patient who is unlikely to be followed-up after delivery. * immunosuppressed patients: i.e., taking systemic immunosuppressant or steroids (e.g. transplant patients; not including steroids for lung maturity), hiv with cd4\<200, or other. * decision to use other than suture closure (e.g. secondary wound closure, mesh closure). * skin infection. * coagulopathy. * high likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, bowel or adnexal surgery). * allergy to triclosan. * incarcerated individuals.
surgical treatment of pelvic joint instability in patients with severe pelvic girdle pain after pregnancy and trauma

Conditions: Pelvic Joint Instability; Pelvic Pain

Summary: pelvic girdle pain (pgp) related to pregnancy is a common reason to sick leave during pregnancy. low back pain and pgp affects about 50% of women during pregnancy. most of the women recover, however about 10% of the women still have complaints after birth. most patients have positive effect from conservative treatment, but unfortunately some do still have much pain despite intensive conservative rehabilitation. surgery has been tried on these women with various results. surgical treatment is controversial and there is a lack of documentation. the investigators will operate 20 patients with arthrodesis to the sacroiliac joint and symphysis. radiostereometric analysis (rsa) will be used to evaluate the joint movement in different part of the process. hypothesis: severe pelvic girdle pain is caused by pelvic joint instability in some cases and surgically fixation of the affected joints can help these women to get back to a normal life.


Eligibility criteria:
inclusion criteria: * pain in one or more pelvic joints. * minimum 2 positive clinical tests. * high pain and disability score * tried adequate physiotherapy without effect. exclusion criteria: * known psychiatric diagnosis * other spine pathology * ct verified ankylosis * bmi\>30

Keywords: sacroiliac pain sacroiliac instability pelvic girdle pain sacroiliac arthrodesis arthrodesis surgery
optimal timing of misoprostol administration prior to office hysteroscopy

Conditions: Pain

Summary: the aim of this study was to determine whether misoprostol administered 12 hours before office hysteroscopy can relieve pain more effectively compared with misoprostol administered 3 hours before office hysteroscopy.

the interval between misoprostol administration and office hysteroscopy may have an influence on its effectiveness in pain reduction. there are limited data on the optimal interval from administration of misoprostol and office hysteroscopy. in previous studies, time interval from administration of misoprostol and office hysteroscopy ranged between 2 hours and 24 hours. till now no studies have yet investigated the optimal timing of misoprostol administration prior to office hysteroscopy or operative hysteroscopy. the aim of this study was to determine whether misoprostol administered 12 hours before office hysteroscopy can relieve pain more effectively compared with misoprostol administered 3 hours before office hysteroscopy

Eligibility criteria:
inclusion criteria: * nulliparous patients who have an indication for office hysteroscopy exclusion criteria: * parous patients, menopausal patients and patients with cervical pathology, and previous cervical surgery will be excluded from the study. moreover, patients with severe vaginal bleeding, acute pelvic inflammatory disease, glaucoma, allergy to misoprostol, cardiac, liver or kidney diseases

Keywords: misoprostol, pain, office hysteroscopy
turkish nationwide survey of glycemic and other metabolic parameters of patients with diabetes mellitus

Conditions: Diabetes Mellitus

Summary: this study evaluates the overall cardiovascular risk status and best predictors of optimal metabolic control of turkish adult patients with diabetes mellitus.

diabetes mellitus is one of the most common chronic diseases with an increasing prevalence worldwide.the prevalence of diabetes is also increased significantly in turkey, from 7.2 % in 2002 to 13.7% in 2012.this increasing prevalence leads to serious public health problems and a significant economic burden. therefore, the optimal treatment of diabetes and prevention of diabetic complications, especially the cardiovascular outcomes, is utmost important. although achieving glycemic targets in patients with diabetes is of great importance, blood glucose is not the only predictor of cardiovascular outcome in diabetes. optimization of other metabolic parameters such as lipids, arterial blood pressure (abp), and body weight as well as a healthy lifestyle are utmost important. as there is hardly enough data about glycemic and other metabolic control parameters in turkish adult patients with type 1 or type 2 diabetes, this nationwide survey was performed.

Eligibility criteria:
inclusion criteria: * patients with type 1 or type 2 diabetes * upper than 18 years old * to be under follow-up in the same center for at least one year. exclusion criteria: * pregnancy * younger than 18 years old, * history of decompensated liver disease, * history of psychiatric disorders interfering cognition or compliance * history of bariatric surgery * history of renal replacement therapy.

Keywords: cardiovascular risk status optimal metabolic control
a two-week study assessing the onset of effect questionnaire administered pre-dose versus post-dose in adult subjects

Conditions: Asthma

Summary: the purpose of this study is to demonstrate whether subjects respond similarly to the onset of effect questionnaire (oeq) administered pre-dose versus post-dose, while receiving symbicort® pmdi 80/4.5 μg x 2 actuations twice daily or budesonide hfa pmdi 80 μg x 2 actuations twice daily.


Eligibility criteria:
inclusion criteria: * male or female, \> 18 years of age * mild to moderate asthma requiring treatment with an inhaled corticosteroid * diagnosis of asthma for at least 6 months exclusion criteria: * subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular) * subjects with severe asthma, as judged by investigator * any significant disease or disorder that may jeopardize a subject's safety

Keywords: mild asthma moderate asthma
randomized trial of cobra pzf stenting to reduce duration of triple therapy

Conditions: Angina, Stable; Angina, Unstable; Anticoagulants

Summary: the purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the cobra pzf stent plus 14-day dual anti-platelet therapy (dapt) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard fda-approved drug eluting stent (des) plus 3 or 6-month dapt.


Eligibility criteria:
inclusion criteria: * patients older than age 18 with ischemic symptoms (stable or unstable angina or nstemi without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels). * patient receiving or with an indication for new treatment with long-term oral anticoagulation with a coumadin derivatives or non-vitamin k oral anticoagulants. * written, informed consent exclusion criteria: * cardiogenic shock * target lesion located in left main trunk * bifurcation interventions with a planned 2-stent strategy * vessel size too small for implantation of a 2.5 mm stent by visual estimation * patient requiring staging pci procedure within 6 months after the index procedure * patients requiring dapt for more than 2 weeks after the index procedure * contraindications or allergy to cobalt, chromium, platinum, polyzene-f, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months * relevant hematologic deviations: platelet count \ 600x10\^9 cells/l * active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection * malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance * pregnancy, present (positive pregnancy test), suspected or planned, breast feeding * known allergy or intolerance to the study medications: asa, clopidogrel, coumadin and its derivatives * patient's inability to fully cooperate with the study protocol
efficacy of novel drug-combinations for relief of psoriasis

Conditions: Psoriasis

Summary: endure is a prospective, observational study aimed to document clinical response and side effects associated with compounded psoriasis medications when prescribed as routine care. as a secondary initiative, this study will assess methotrexate systemic absorption and toxicity in patients prescribed a methotrexate-containing compounded formulation.

in this prospective, observational study, change in psoriasis plaque appearance, per the psoriasis area severity index (pasi) tool, will be evaluated after using a topical psoriasis cream containing at least 3 of the following: corticosteroid, methotrexate, vitamin d3 or synthetic analog, retinoid acid, or urea, or a topical shampoo or spray containing a corticosteroid and vitamin d3 or synthetic analog. the change in quality of life will be assessed during all visits using the skindex-16 assessment tool. in patients receiving a methotrexate-containing formulation, a sub-study will be available as an option, where laboratory values (methotrexate levels, complete blood count, liver function tests, etc.) will be obtained to confirm that methotrexate absorption is negligible.

Eligibility criteria:
inclusion criteria: * \>18 years of age * diagnosis of psoriasis vulgaris * being initiated on a topical compounded medication for psoriasis from medimix specialty pharmacy containing at least 3 of the following ingredients as part of standard of care: corticosteroid, methotrexate, retinoic acid, vitamin d3 or synthetic analog, urea, and/or a shampoo/spray containing a corticosteroid and vitamin d3 or synthetic analog for the first time. exclusion criteria: * pregnancy \& nursing * active infectious disease * kidney abnormalities * blood deficiencies * alcohol consumption * immunodeficiency syndromes * history of systemic psoriasis medications, including conventional dmards, oral retinoids, oral calcineurin inhibitors, tnf-inhibitors, and monoclonal antibodies within the past 120 days * current or planned use of concomitant psoriasis medications and/or phototherapy * any additional health conditions or concomitant use of other prescription/over-the-counter products that may confound the study results at the discretion of the study investigators

Keywords: efficacy of novel drug combinations for relief of psoriasis
safety and tolerability of interferon-beta-1a and estroprogestins association in ms patients

Conditions: Multiple Sclerosis

Summary: clinical and experimental evidences suggests an immunomodulatory effect of sex hormones in multiple sclerosis. the role of oral estroprogestins in the pathogenesis and in the clinical course of the disease is actually unknown. the aim of the study is to investigate safety and tolerability of association of estroprogestins in two different doses with interferon-beta 1a in patients with relapsing-remitting multiple sclerosis.

phase 2, randomised, single blind, three arms study. follow-up of 24 months. the study will include relapsing-remitting multiple sclerosis female patients. patients will be equally randomised into three groups: 1) patients treated with ifn-beta 1a (44 mcg for three times a week), 2) patients treated with ifn-beta 1a and lower-dose estroprogestins (desogestrel 150 mcg, etinilestradiol 20 mcg), 3) patients treated with ifn-beta 1a and higher-dose estroprogestins (desogestrel 25 mcg, etinilestradiol 40 mcg). safety and tolerability of the treatment will be evaluated using neurological examination and mri analysis. a complete neurological examination (with edss) will be performed at month 0, 6, 12, 18 and 24. mri examination will be assessed at baseline and at month 12 and 24. in the same day of mri examination we'll collect blood samples for hormonal analysis (we'll measure sex hormones in the follicular and in the luteal phase of a single menstrual cycle). during the follow-up patients will be evaluated also with: ms-functional composite at month 0, 6, 12, 18, 24; neuropsychological evaluation at month 0, 12, 24; fatigue severity scale at month 0, 12, 24; hamilton depression scale at month 0, 12, 24; quality of life scale (msqol54) at month 0, 12, 24.

Eligibility criteria:
inclusion criteria: * female patients * clinically definite relapsing-remitting ms according to the mcdonald criteria * age between 18-40 y.o. * edss from 0 to 4.0, inclusive exclusion criteria: * history of migraine or thromboembolic events * reproductive system disorders * pregnancy or suspension of pregnancy within 12 months prior to randomisation * prior use of estroprogestins within the last 3 months prior to randomisation * prior use of immunosuppressive drugs within the last 12 months prior to randomisation * prior use of immunomodulating drugs within the last 6 months prior to randomisation * prior use of corticosteroids within the last 3 months prior to randomisation * have clinical relapse 30 days prior to randomisation

Keywords: multiple sclerosis estroprogestins interferon-beta sex hormones mri
visual field changes and oct angiographic chorioretinal changes in patients with primary open angle glaucoma

Conditions: Visual Field; OCT Angiography; Chorioretinal Changes; Primary Open Angle Glaucoma

Summary: this study aimed to assess the correlation between visual field changes and optical coherence tomography (oct) angiography changes of retinal nerve fiber layer in patients with primary open angle glaucoma.

glaucoma is the leading cause of irreversible blindness worldwide. since glaucomatous damage is preventable but irreversible, an early diagnosis and close follow-up of glaucoma patients are primordial. optical coherence tomography angiography (octa) is a recently developed, noninvasive imaging modality that detects blood flow through the motion contrast generated by red blood cells. currently, there are 2 groups of complementary exams used for the diagnosis and follow-up of glaucoma patients: structural (where oct has a considerable role) and functional (visual field) optic nerve measurements, both technologies have strengths and limitations. a new technology for diagnosis and follow-up that can avoid the limitations summarized above is lacking. octa seems to be a good candidate for such a role, oct can detect the doppler frequency shift of the backscattered light that provides information on blood flow.

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma patients. exclusion criteria: 1. hazy media. 2. diabetic retinopathy. 3. uveitis. 4. other glaucomas * acute congestive glaucoma * secondary glaucomas